Journal
THERAPEUTIC ADVANCES IN HEMATOLOGY
Volume 5, Issue 4, Pages 121-133Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620714539906
Keywords
B-cell receptor signaling; Bruton's tyrosine kinase; chronic lymphocytic leukemia; ibrutinib; mantle cell lymphoma; refractory non-Hodgkin's lymphoma
Categories
Ask authors/readers for more resources
Aberrant signaling of the B-cell receptor pathway has been linked to the development and maintenance of B-cell malignancies. Bruton's tyrosine kinase (BTK), a protein early in this pathway, has emerged as a new therapeutic target in a variety of such malignancies. Ibrutinib, the most clinically advanced small molecule inhibitor of BTK, has demonstrated impressive tolerability and activity in a range of B-cell lymphomas which led to its recent approval for relapsed mantle cell lymphoma and chronic lymphocytic leukemia. This review focuses on the preclinical and clinical development of ibrutinib and discusses its therapeutic potential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available